- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05204472
Thalamic-Burst-DBS for Neuropathic Pain
Burst-Deep Brain Stimulation of the Thalamus for Neuropathic Facial Pain and Central Poststroke Pain: a Prospective, Randomized Cross-over Feasibility Trial
Central post-stroke pain (CPSP) is a neuropathic pain syndrome and one of the major sequelae after ischemic or hemorrhagic cerebral stroke.
Recently, a modified stimulation paradigm has been developed in the field of spinal cord stimulation (SCS) for a variety of neuropathic pain disorders. To date, this stimulation paradigm has not yet been evaluated systematically for deep brain stimulation to treat neuropathic pain disorders.
The purpose of this clinical investigation is to investigate if Burst-DBS of the thalamus is more effective compared to classical continuous low-frequency stimulation DBS to reduce the subjective pain intensity in patients with chronic neuropathic pain after stroke or in patients with neuropathic facial pain.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Central post-stroke pain (CPSP) is a neuropathic pain syndrome and one of the major sequelae after ischemic or hemorrhagic cerebral stroke. Neuropathic facial pain (NFP) can arise after damage to or affection of the trigeminal nerve caused by trauma, infection or postsurgery and results in characteristic burning and shooting pain of the affected area in the face.
The lack of effective analgesic treatment for these two conditions continues to be an unmet medical need and led to the investigation of alternative treatments of CPSP and NFP such as deep brain stimulation (DBS). DBS is an invasive neuromodulation therapy that consists of placing small electrodes into confined anatomical structures of the brain to deliver small therapeutic currents.
Recently, a modified stimulation paradigm has been developed in the field of spinal cord stimulation (SCS) for a variety of neuropathic pain disorders. This so-called burst stimulation provides pulse trains of five high-frequency pulses at 500 Hz (= 500 Hz spike frequency) occurring 40 times a second (= 40 Hz burst frequency). Burst SCS has been demonstrated to provide a better pain relief compared to classical tonic (continuous application of 50 Hz stimulation) SCS without causing paresthesia. To date, this stimulation paradigm has not yet been evaluated systematically for deep brain stimulation to treat neuropathic pain disorders.
The purpose of this clinical investigation is to investigate if Burst-DBS of the thalamus is more effective compared to classical continuous low-frequency stimulation DBS to reduce the subjective pain intensity in patients with chronic neuropathic pain after stroke or in patients with neuropathic facial pain.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andreas Nowacki, MD
- Phone Number: +41 31 6320014
- Email: andreas.nowacki@insel.ch
Study Contact Backup
- Name: Söll Nicole
- Phone Number: +41316323164
- Email: nicole.soell@insel.ch
Study Locations
-
-
-
Bern, Switzerland, 3000
- Recruiting
- Dep. of Neurosurgery, Bern University Hospital
-
Contact:
- Andreas Nowacki, MD
- Phone Number: +41 31 632 2409
- Email: andreas.nowacki@insel.ch
-
Contact:
- Claudio Pollo, MD
- Phone Number: +41 31 632 2409
- Email: claudio.pollo@insel.ch
-
Sub-Investigator:
- Andreas Nowacki, MD
-
Principal Investigator:
- Claudio Pollo, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent
- Age 18-75 years
- Patients suffering from chronic (duration > 12 months) unilateral neuropathic pain caused by an ischemic or haemorrhagic cerebral stroke or
Patients suffering from chronic (duration > 12 months) unilateral neuropathic facial pain due to one of the following causes:
- post-herpes-zoster-neuralgia,
- posttraumatic, neuropathic facial pain,
- atypical trigeminal neuralgia after surgical intervention
- Severe baseline pain intensity (VAS score > 6/10) considered as resistant to medication specific to neuropathic pain at sufficient doses and durations (including at least antiepileptics and antidepressants)
Exclusion Criteria:
- Significant cognitive impairment (total MOCA score < 1.5 standard deviations from age- and education adapted mean values),
- DSMIV axis I or II psychiatric disorder
- Relevant psychosocial risk factors (any of): history of other chronic pain syndrome, pain catastrophizing, substance abuse, secondary gain
- Contra-indication to surgery, anesthesia, or MRI
- Known or suspected non-compliance or inability to operate the DBS system
- Woman with childbearing potential
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia. etc. of the subject
- Participation in another interventional clinical trial within 30 days prior to this trial or during the trial
- Previous enrollment into the current trial
- Enrolment of the investigator's family members, employees, and other dependent persons
- Patients who are planned to undergo diathermy, electroshock therapy or transcranial magnetic stimulation (TMS)
- Patients with implanted electric devices (i.e. cardiac defibrillator, pacemaker)
- Patients who are at poor surgical risk (i.e. patients with multiple severe illnesses or active general infections)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Burst DBS first, Tonic DBS second
10 days of Burst-stimulation followed by 10 days of active tonic stimulation (Burst-DBS -> tonic-DBS)
|
Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation: 12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period). Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation: 12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period). |
Active Comparator: Tonic DBS first, Burst DBS second
10 days of active tonic stimulation followed by 10 days of Burst-stimulation (tonic-DBS -> Burst-DBS)
|
Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation: 12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period). Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation: 12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage reduction of pain intensity
Time Frame: 2 weeks after surgery
|
Percentage reduction of pain intensity on the numeric rating scale (NRS 1-10) after each stimulation-block compared to the baseline pain intensity before surgery.
Score 0-10 with 0 representing no pain, and 10 maximum pain intensity
|
2 weeks after surgery
|
Percentage reduction of pain intensity
Time Frame: 1 week after surgery
|
Percentage reduction of pain intensity on the numeric rating scale (NRS 1-10) after each stimulation-block compared to the baseline pain intensity before surgery.
Score 0-10 with 0 representing no pain, and 10 maximum pain intensity
|
1 week after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of pain intensity on the numeric rating scale
Time Frame: 12 months after surgery
|
Efficacy of DBS after 12 months of open-label stimulation measured as the percentage change of pain intensity on the numeric rating scale compared to baseline.
Score 0-10 with 0 representing no pain, and 10 maximum pain intensity
|
12 months after surgery
|
Percentage change of pain intensity on the Neuropathy pain scale
Time Frame: 12 months after surgery
|
Efficacy of DBS after 12 months of open-label measured as the percentage change of pain intensity on the Neuropathy pain scale (DN-4) compared to baseline.
Score 0-10 with 0 representing no pain, and 100 maximum pain intensity
|
12 months after surgery
|
Percentage improvement of quality of life measured by the EuroQoL 5D-5L
Time Frame: 12 months after surgery
|
Efficacy of DBS after 12 months of open-label measured as the percentage improvement of quality of life measured by the EuroQoL 5D-5L questionnaire (Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/ Depression (rating from no problems to extreme problems) and health status self rating by patient (Score 0-100, 0 the worst health and 100 the best health)) compared to baseline.
|
12 months after surgery
|
Change of dosage of analgesic medication(s)
Time Frame: 12 months after surgery
|
Change of dosage of analgesic medication(s) at 12 months of open-label stimulation measured as the total dosage in mg per medication per day with reference to baseline
|
12 months after surgery
|
Efficacy of DBS
Time Frame: 12 months after surgery
|
Efficacy of DBS after 12 months of open-label stimulation measured as the percentage improvement of depressive symptoms by the BDI questionnaire compared to baseline
|
12 months after surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andreas Nowacki, MD, Insel Gruppe AG, University Hospital Bern
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DBS for neuropathic pain
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
-
AstraZenecaCompletedNociceptive Pain | Peripheral Neuropathic PainUnited Kingdom
Clinical Trials on Burst DBS
-
University of Southern CaliforniaRecruitingParkinson DiseaseUnited States
-
Allegheny Singer Research Institute (also known...Boston Scientific CorporationRecruitingParkinson Disease | Deep Brain StimulationUnited States
-
Deep Brain Innovations LLCTerminatedParkinson DiseaseUnited States
-
Chinese PLA General HospitalNot yet recruitingCervical DystoniaChina
-
University Medical Center GroningenUnknown
-
Jaimie M. HendersonHarvard Medical School (HMS and HSDM); The Cleveland Clinic; Weill Medical College... and other collaboratorsCompletedTBI (Traumatic Brain Injury)United States
-
University of Southern CaliforniaCompletedParkinson DiseaseUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingCentral Nervous System Diseases | Essential Tremor | Deep Brain Stimulation | Magnetic Resonance | Diffusion Tensor ImagingNetherlands
-
University of TorontoNot yet recruiting
-
Ruijin HospitalNational Natural Science Foundation of China; Icahn School of Medicine at Mount... and other collaboratorsWithdrawnObsessive Compulsive DisorderChina